Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Keratosis, Actinic 6Carcinoma, Basal Cell 4Bowen's Disease 2Warts 1Uterine Cervical Dysplasia 1Keratosis 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

pembrolizumab 20Cisplatin 17Cetuximab 13Docetaxel 11Paclitaxel 9Carboplatin 9Radiotherapy 8Fluorouracil 6cemiplimab 5130-nm albumin-bound paclitaxel 5Bleomycin 4Radiation 3Pemetrexed 3Panitumumab 3Nivolumab 3Gemcitabine 3Albumin-Bound Paclitaxel 3vandetanib 2talimogene laherparepvec 2selinexor 2motexafin gadolinium 2figitumumab 2brigatinib 2avelumab 2atezolizumab 2alpha-2'-deoxythioguanosine 2advexin 2Taxes 2ON 01910 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Squamous Cell × methyl 5-aminolevulinate × Clear all
NCT00472459 2025-04-18

Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

Galderma R&D

Phase 3 Completed
82 enrolled 20 charts
Dermatologic

Bowen's Disease, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Warts, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡